Minor correction of the Interim report for January – June 2017

STOCKHOLM, August 8th 2017, Moberg Pharma AB (OMX: MOB) has corrected a minor error in the first text paragraph on page 8 of the Interim report for January – June 2017. A table figure (including comparison) was incorrectly stated in the referring text. This has been corrected and the updated version of the report has been published on the company’s web page.

In the Interim report for January – June 2017, a minor mistake in the first text paragraph on page 8 “Revenue development in the second quarter” has been corrected. A table figure (including comparison) was incorrectly stated in the referring text. This has been corrected and the updated version of the report has been published on the company’s web page. The correct content is the following:

“Net sales amounted to SEK 136.1 million (71.3), an increase of 91% compared with the previous year. Kerasal Nail® accounted for SEK 53.2 million (49.0), Dermoplast® accounted for SEK 26.0 million (0), while other products including New Skin®, contributed with SEK 56.8 million (22.3). Together, global sales of the three largest brands Kerasal Nail®, Dermoplast® and New Skin® make up more than two-thirds of revenue and an even higher percentage of profitability.” 

About this information
This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 06:30 p.m. (CET) on August 8th 2017.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se
Anna Ljung, CFO, telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se 

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®, Domeboro® and Fiber Choice®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts